Docetaxel / TGF-β Cancer Research Results

docx, Docetaxel: Click to Expand ⟱
Features:
Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction Microtubule dynamics ↓; mitotic progression fails Also impacts normal proliferating cells P, R Core cytotoxic mechanism Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2 Mitotic arrest (G2/M checkpoint pressure) G2/M arrest ↑; proliferation ↓ Bone marrow / GI epithelium vulnerability ↑ R, G Cell-cycle blockade Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3 Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe Apoptosis ↑ (context); caspase activation ↑ ↔ / tissue injury possible at high exposure G Death execution Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4 Neutropenia / marrow suppression (on-target toxicity) — Neutrophils ↓; febrile neutropenia risk ↑ R, G Dose-limiting toxicity Major clinical constraint; risk increases with dose and interacting drugs.
5 Hypersensitivity reactions — Hypersensitivity risk ↑ (especially early infusions) P, R Acute infusion risk Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6 Fluid retention / capillary leak tendency — Fluid retention ↑ (can be severe) R, G Key non-hematologic toxicity Dexamethasone premedication is standard to reduce incidence and severity.
7 Combination leverage (sensitization with other agents) Synergy reported in multiple regimens Toxicity may ↑ depending on partner drug G Regimen-driven efficacy Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8 Pharmacokinetics (CYP3A4 metabolism) Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers Exposure shifts → toxicity/efficacy shifts P, R Interaction driver Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9 Grapefruit / intestinal CYP3A4 inhibition (interaction risk) Potential exposure ↑ (context) Potential toxicity ↑ (context) P, R Diet–drug interaction Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10 Parameter dependence (dose/schedule; weekly vs q3wk) Mechanism constant; tolerability differs by schedule Toxicity profile differs by schedule — Translation constraint Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11 ROS generation (secondary to mitotic stress) ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported) Oxidative injury possible R, G Stress amplification ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12 NRF2 antioxidant response NRF2 ↑ (adaptive; reported in resistant models) Protective antioxidant upshift R, G Resistance mechanism NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
  • R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
  • G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)
TGF-β, transforming growth factor-beta: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS TCGA
Type:
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses.
Anti-inflammatory cytokine.
In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling.
- In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β.
- TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion.

Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses.

Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers.
 - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment.

High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types.
Scientific Papers found: Click to Expand⟱
26- EGCG,  QC,  docx,    Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
- vitro+vivo, Pca, PC3
BAD↓, cl‑PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓, chemoP↑, ChemoSen↑, TumVol↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

BAD↓, 1,   Bax:Bcl2↑, 1,   Casp7↑, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

FGF↓, 1,   SCF↓, 1,  

Migration ⓘ

Ki-67↓, 1,   TGF-β↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

IκB↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   TumVol↓, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TGF-β, transforming growth factor-beta
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:178  Target#:304  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page